2 results match your criteria: "Cambridge University Hospital Foundation NHS Trust[Affiliation]"
Comparative Safety and Effectiveness of Ustekinumab and Anti-TNF in Elderly Crohn's Disease Patients.
Inflamm Bowel Dis
August 2024
Department of Gastroenterology, Cambridge University Hospital Foundation NHS Trust, Cambridge, United Kingdom.
Background: Biologic therapies are associated with increased infection risk among elderly patients with inflammatory bowel disease (IBD). However, there are few data on the safety and effectiveness of ustekinumab compared with anti-tumor necrosis factor (anti-TNF) agents in the elderly.
Methods: The study sought to compare the safety and effectiveness of ustekinumab and anti-TNF agents in elderly Crohn's disease (CD) patients.
Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Dig Dis Sci
May 2023
Department of Gastroenterology, Leeds University Teaching Hospital NHS Trust, Leeds, UK.
Background: Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients, and thus, alternative biologics may be preferable. However, little comparative data exist on the safety and efficacy of vedolizumab and ustekinumab in elderly IBD patients.
Aims: To compare the safety and effectiveness of ustekinumab and vedolizumab in elderly Crohn's disease patients.